Helping Patients With ESRD and Earlier Stages of CKD to Quit Smoking

Publication date: Available online 13 April 2018 Source:American Journal of Kidney Diseases Author(s): Perry Formanek, Elizabeth Salisbury-Afshar, Majid Afshar Among the many adverse effects of tobacco exposure is the increased risk for progression of kidney disease. Individuals with chronic kidney disease (CKD), who already face increased cardiovascular event rates compared to the general population, are at even greater risk if they smoke. Despite these risks and the increased focus on smoking cessation in the general population in recent years, national guidelines have not specifically targeted individuals with CKD. There are similarly sparse data specific to individuals with CKD regarding the safety and efficacy of evidence-based smoking cessation modalities. This review aims to identify the risks of nicotine dependence in individuals with CKD and the potential benefits of smoking cessation; discuss current strategies for smoking cessation, including behavioral and pharmacologic therapies such as varenicline; and extrapolate these interventions to the unique challenges of this population. Much of the data presented stem from evidence for the general population but are described with additional consideration in dosing of nicotine replacement therapy, as well as non-nicotine pharmacotherapy and treatment modality for individuals with CKD.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research

Related Links:

Authors: Dayanand P, Sandhyavenu H, Dayanand S, Martinez J, Rangaswami J Abstract Vascular calcification is known to be a strong risk factor for cardiovascular adverse events and mortality. Atherosclerosis, diabetes, aging, abnormal bone mineral homeostasis and high uremic milieu such as chronic kidney disease are major factors that contribute to the progression of vascular calcification. Several mechanisms such as the osteoblastic transition of vascular smooth muscle cells in response to oxidative stress have shed light on the active nature of vascular calcification, which was once thought to be a passive process....
Source: Current Cardiology Reviews - Category: Cardiology Tags: Curr Cardiol Rev Source Type: research
Conclusions: These data suggest that in differentiated proximal tubules energetic hyperactivity is promoted concurrently with organ fibrogenesis.Cell Physiol Biochem 2018;47:1338 –1351
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Condition:   CKD Stage 5 Interventions:   Drug: EffCaMgCit;   Other: CaAcS Sponsor:   University of Texas Southwestern Medical Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The proclamation that “the greatest medicine of all is to teach people how not to need it” (Hippocrates. 460-370 BC, Greece) is the basic principle of primary disease prevention, which aims to prevent disease before it ever occurs. Preventing exposures to hazards that cause disease, such as altering unhealthy behavio rs, is one example of primary disease prevention. Secondary or tertiary disease prevention, however, refers to reducing the impact of a disease that has already occurred, or limiting the impact of an ongoing illness that has lasting effects, respectively.
Source: Journal of Renal Nutrition - Category: Urology & Nephrology Authors: Tags: Editorial Source Type: research
Authors: Gorostidi M, Sánchez-Martínez M, Ruilope LM, Graciani A, de la Cruz JJ, Santamaría R, Del Pino MD, Guallar-Castillón P, de Álvaro F, Rodríguez-Artalejo F, Banegas JR Abstract BACKGROUND: Chronic kidney disease (CKD) is a public health problem worldwide. We aimed to estimate the CKD prevalence in Spain and to examine the impact of the accumulation of cardiovascular risk factors (CVRF). MATERIAL AND METHODS: We performed a nationwide, population-based survey evaluating 11,505 individuals representative of the Spanish adult population. Information was collected th...
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - Category: Urology & Nephrology Tags: Nefrologia Source Type: research
Background: Chronic Kidney Disease (CKD) is a major public health problem and is increasingly being recognized as an important driver of costs in all health care systems. The diversity of outcomes for people living with CKD is in part due to variability in biology, access to care, environmental factors, and health care system differences. The International Society of Nephrology (ISN), working in collaboration with its partners, has evolved into a philanthropic organization, from a traditional medical society, committed to a vision that sees “a future where all people have access to sustainable kidney health”. A...
Source: Annals of Nutrition and Metabolism - Category: Nutrition Source Type: research
Background: Type 2 diabetes, chronic kidney disease (CKD) and its cardiovascular complications are increasing as health problems worldwide. These diseases are interrelated with overlapping occurrence and once diabetes is established, the risk of cardiorenal disease is dramatically elevated. Thus, a search for unifying modifiable risk factors is key for effective prevention.Summary: Elevated fasting plasma concentration of vasopressin, measured with the marker copeptin, predicts new onset type 2 diabetes as well as renal function decline. Furthermore, we recently showed that increased plasma copeptin concentration independe...
Source: Annals of Nutrition and Metabolism - Category: Nutrition Source Type: research
Background: Diabetic nephropathy has become the most common cause of chronic kidney disease (CKD). Despite the progress accomplished in therapy, the prevalence of renal disorders remains high. Some modifiable factors driving the increase in incidence of CKD, in diabetes and other settings, might have been overlooked. Consistent evidence supports a role for vasopressin, hydration state, and urine concentration in kidney health.Summary: Plasma vasopressin is elevated in diabetes, even if metabolic control is good. Several epidemiological studies have pointed to a positive association between markers of vasopressin secretion ...
Source: Annals of Nutrition and Metabolism - Category: Nutrition Source Type: research
The risk assessment tool from the recent Kidney Disease: Improving Global Outcomes conference adds another prediction model for the risk of developing advanced chronic kidney disease and potential need for dialysis.1 None of the existing prediction models use a patient ’s rate of loss of estimated glomerular filtration rate (eGFR). Both current eGFR and the magnitude of past eGFR decline contribute substantially to the risk of end-stage renal disease.2 Furthermore, a graph of all previous eGFR values is an effective visual aid for shared decision-making and can be a useful predictor of when clinical events and treatm...
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Letter to the Editor Source Type: research
Fibroblast growth factor 23 (FGF23) has appeared as a hormone that is massively elevated in patients with chronic kidney disease. Whether FGF23 is a risk factor that associates with cardiac pathologies and cardiovascular mortality, as suggested by a variety of clinical studies, or additionally acts as a causative factor that induces cardiac injury, as more recently indicated by cell culture and animal studies, is under debate and the center of many ongoing experimental studies.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Commentary Source Type: research
More News: Cardiology | Cardiovascular | Chantix | Chronic Kidney Disease | Heart | Nicotine | Nicotine Replacement Therapy | Smokers | Urology & Nephrology